Ultragenyx Pharmaceutical (RARE) Receivables - Other (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Receivables - Other data on file, last reported at $1.0 million in Q1 2026.

• Quarterly Receivables - Other fell 58.33% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (down 58.33% YoY) and the FY2025 annual result came in at $1.0 million, down 50.0% from the prior year.
• Receivables - Other was little changed at $1.0 million in Q1 2026 per RARE's latest filing, from $1.0 million in the prior quarter.
• Across five years, Receivables - Other topped out at $12.7 million in Q1 2023 and bottomed at $200000.0 in Q1 2024.
• The 5-year median for Receivables - Other is $2.1 million (2025), against an average of $2.7 million.
• The widest annual swing landed in 2024, when Receivables - Other tumbled 98.43%; it then soared 1100.0% in 2025.
• Tracing RARE's Receivables - Other over 5 years: stood at $6.4 million in 2022, then plunged by 82.81% to $1.1 million in 2023, then jumped by 81.82% to $2.0 million in 2024, then tumbled by 50.0% to $1.0 million in 2025, then changed by 0.0% to $1.0 million in 2026.
• Per Business Quant, the three latest RARE Receivables - Other figures stand at $1.0 million (Q1 2026), $1.0 million (Q4 2025), and $2.1 million (Q3 2025).

Peer Comparison